(106.) NCT02862938, A Randomized, Sham Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Intravitreal Implantation of NT-501 Encapsulated Cell Therapy
for the Treatment of Glaucoma.
Encapsulated cell therapy
aims to unleash the therapeutic potential of cells to treat serious diseases without the need for immunosuppression.
Neurotech Pharmaceuticals Inc, a biotechnology company focused on developing transformative therapies for chronic eye diseases, revealed on Monday that the US Food and Drug Administration (FDA) has accepted Neurotech's ability to proceed with its Investigational New Drug (IND) application to conduct a Phase 2 clinical study of NT-503 Encapsulated Cell Therapy
And Thomas Chang's laboratory at McGill University pioneered encapsulated cell therapy
for liver failure and as an artificial red blood cell.